Glioma patients with high expression of CDC42EP3 underwent much shorter overall survival (Fig. 1B) and more likely to suffer from tumor recurrence (p < 0.001, Table 2) than those with low level of CDC42EP3. The gene discussed is CDC42EP3; the disease is central nervous system cancer.